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Abstract	
MYC genes have both essential roles during normal development and exert oncogenic 
functions during tumorigenesis. Expression of a dominant-negative allele of MYC 
termed OmoMYC can induce rapid tumor regression in mouse models with little 
toxicity for normal tissues. How OmoMYC discriminates between physiological and 
oncogenic functions of MYC is unclear. We have solved the crystal structure of 
OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in 
the same manner as the MYC/MAX heterodimer. OmoMYC attenuates both MYC-
dependent activation and repression by competing with MYC/MAX for binding to 
chromatin, effectively lowering MYC/MAX occupancy at its cognate binding sites. 
OmoMYC causes the largest decreases in promoter occupancy and changes in 
expression on genes that are invaded by oncogenic MYC levels. A signature of 
OmoMYC-regulated genes defines subgroups with high MYC levels in multiple tumor 
entities and identifies novel targets for the eradication of MYC-driven tumors. (149 
words) 		
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Introduction 
A large body of evidence shows that the deregulated and enhanced expression of one of 
three members of the MYC gene family (MYC, MYCN, MYCL) contributes to the genesis of 
multiple human tumors1. MYC proteins are transcription factors that bind to virtually all 
promoters with an open chromatin structure as well as to thousands of enhancers together 
with an obligate heterodimerization partner, MAX (for recent reviews, see:1-3). They can both 
activate and repress genes transcribed by RNA polymerase II and, in some circumstances, 
enhance expression of all genes. In addition, MYC proteins can stimulate transcription of 
genes transcribed by RNA polymerases I and III. 	
Depletion of MYC in tissue culture or deletion of MYC or MAX genes during mouse 
development shows that MYC/MAX complexes have essential functions during embryonic 
development and are necessary for growth of multiple cell types in vivo and in culture4-6. This 
correlates with the observation that multiple target genes of MYC encode proteins involved in 
basic cellular processes, including protein translation, cell cycle progression, DNA synthesis 
and intermediary metabolism1. A plethora of mutations that initiate tumorigenesis leads to 
constitutive, growth factor-independent expression of MYC. During tumor progression, there 
is a strong selection for further increases in MYC expression to supra-physiological levels, 
suggesting that such high levels of MYC provide an additional advantage to tumor cells7, 8. 
Two models have been proposed to account for this selective pressure: in one, oncogenic 
levels of MYC acquire new functions not shown by physiological MYC such as effects on the 
tumor microenvironment9, angiogenesis and response to hypoxia10, 11, resistance to 
antimitogenic signals12, 13, as well as stem cell function and metastasis14. In the second 
model, oncogenic MYC levels drive physiological processes such as translation to supra-
physiological levels and tumor-specific phenotypes arise as stress responses to these 
primary events15, 16. 
The clearest demonstration that physiological and oncogenic functions of MYC can be 
discriminated comes from the study of a dominant-negative allele of MYC termed 
OmoMYC17. Mice expressing OmoMYC in a doxycycline-inducible manner display rapid 
Jung et al.                           OmoMYC structure and function 	
- 4 -	
regression of lung adenocarcinomas, glioblastomas and pancreatic tumors but show only 
mild and fully reversible effects on proliferation in normal tissues9, 17, 18. As consequence, 
intermittent induction of OmoMYC (“metronomic treatment”) enables long-term suppression 
of tumor growth arguing that therapeutic strategies that mimic OmoMYC may have significant 
efficacy for the treatment of human tumors19. 
OmoMYC comprises the carboxy-terminal basic region, helix-loop-helix and leucine zipper of 
MYC and carries four point mutations in the leucine zipper that are intended to alter its 
dimerization properties20. Here, we present an analysis of the OmoMYC structure, its 
genome-wide chromatin binding and gene regulation to understand its astounding ability to 
discriminate physiological from oncogenic functions of MYC.   
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Results 
OmoMYC is a highly stable homodimer and forms a tight protein-DNA complex	
To understand how OmoMYC regulates gene expression, we expressed a histidine-tagged 
OmoMYC protein in E. coli and purified the recombinant protein to homogeneity using 
sequential metal affinity and cation exchange chromatography (Supplementary Figure 
S1a,b). In parallel, we purified recombinant proteins encompassing the basic region/helix-
loop-helix/leucine zipper (b/HLH/Zip) region of MYC and full length MAX (Supplementary 
Figure S1b). We pursued crystallization of OmoMYC in the absence and presence of an 
oligonucleotide carrying an E-box binding site and solved both the apo- and the DNA bound-
structure of OmoMYC (Figure 1a,b; Supplementary Table S1a,b) at 1.95 Å and 2.70 Å, 
respectively. In both structures OmoMYC forms a homodimer with an overall structure that is 
very similar to those of other b/HLH/Zip structures, in particular to that of MYC/MAX 
heterodimers21 (Supplementary Table S2a,b). 	
Superposition of the apo- and DNA-bound OmoMYC complex showed that the two structures 
are nearly identical with rms deviations of 0.60 Å for all main chain atoms with the exception 
of the basic region, which was not resolved in the apo-structure (Supplementary Table S2a). 
The homodimer is stabilized by multiple ionic and hydrophobic interactions (Figure 1c, 
Supplementary Figure S1c; Supplementary Table S3).  Consistent with the intended design 
of OmoMYC, three out of the four mutations introduced to generate the OmoMYC protein led 
to additional interactions between the two monomers (Figure 1a,c). The newly introduced 
hydrogen bonds are formed between two threonine residues (T63) bridged by water 
molecules as well as the asparagines (N77) of both molecules with an additional interaction 
to lysine 81 in monomer B. Hydrophobic interactions are observed between two isoleucine 
residues (I70) and to lysine 66. Further hydrophobic interactions are observed between 
threonine 63 and leucine 66. Glutamine 76, which is also a mutated residue in OmoMYC, 
faces away from the interface.	
Differences in protein-protein interactions between the OmoMYC homodimer and the 
MYC/MAX heterodimer are not limited to the mutated residues, but can also be identified 
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throughout the entire interface (Figure 1c). OmoMYC also displayed a disulfide bridge 
formed by its penultimate cysteine residues (Figure 1a; Supplementary Figure S1d). Using 
the 'Protein interfaces, surfaces and assemblies' (PISA) tool22, we estimated that the protein-
protein interface of the OmoMYC homodimer is more stable than the MYC/MAX heterodimer 
(ΔG=-41 kcal/mol versus -33 kcal/mol; Supplementary Table S4). Heterodimers of OmoMYC 
with MYC and MAX would contain repulsive interactions or lack stabilizing interactions that 
would lower their stability (Supplementary Figure S1e-g), suggesting that OmoMYC 
preferentially forms homodimers.  
 
In the DNA-bound complex, OmoMYC binds to the major groove of the DNA by forming a 
scissor-like structure at the E-box, which is stabilized via phosphate-backbone interactions 
and base-specific interactions. The latter are mediated via a histidine (H12), glutamate (E16), 
arginine (R20) triad in the basic region (Figure 1b; Supplementary Figure S2a,b). A 
comparison of the protein-DNA interface of OmoMYC to the one of the MYC/MAX DNA 
complex indicates that the basic region of both complexes assume the same contacts to 
DNA, suggesting that OmoMYC could compete with MYC/MAX for E-box binding21 
(Supplementary Figure S2c; Supplementary Table S2a,b). We therefore studied the DNA 
binding properties of all three proteins using a fluorescently labeled oligonucleotide carrying 
a consensus E-box sequence. Recombinant MAX proteins bound to this sequence with high 
affinity, whereas binding of MYC was only detectable at micromolar protein concentrations 
(Figure 2a,b; Supplementary Figure S3a). Consistent with previous results, MAX and MYC 
co-operated in DNA binding and MYC/MAX complexes bound DNA with a higher affinity than 
MAX homodimers (Figure 2a,b; Supplementary Figure S3a,b). OmoMYC homodimers bound 
DNA with an affinity that is even higher than that of MYC/MAX complexes, both in the 
absence and presence of reducing agent (Figure 2a,b; Supplementary Figure S3a). 
Furthermore, OmoMYC formed heterodimers with MYC that bound to DNA with an 
intermediate affinity (Figure 2a,b; Supplementary Figure S3a,b). We were unable to 
unequivocally ascertain whether OmoMYC/MAX heterodimers bind DNA. 
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To demonstrate that OmoMYC homodimers exist in cells, we first briefly exposed cells stably 
expressing OmoMYC to conditions known to oxidize cysteine residues (100 µM H2O2, 5 
min23). Upon treatment of cells with H2O2, virtually all OmoMYC molecules migrated with a 
molecular weight expected of a covalently-linked homodimer in a non-reducing SDS PAGE 
(Figure 2c). Mutation of the penultimate cysteine to serine (OmoMYC-CS) confirmed that this 
residue was involved in dimerization under oxidizing conditions (Figure 2c). Second, we 
stably co-expressed both HA-tagged and FLAG-tagged alleles of OmoMYC in U2OS cells 
and precipitated lysates with α-FLAG antibodies (Figure 2d). These experiments confirmed 
that OmoMYC forms homodimers in cells. The cells express a doxycycline-inducible allele of 
MYC24 and we also expressed a HA-tagged allele of MYC in cells expressing FLAG-
OmoMYC. Probing the immunoprecipitates with α-MYC, α-HA and α-MAX antibodies 
showed that OmoMYC also forms heterodimers with both MYC and MAX in cells (Figure 2d), 
consistent with previous results25. Notably, doxycycline-mediated induction of wtMYC or 
expression of HA-MYC significantly reduced binding of OmoMYC to MAX, but had little effect 
on homodimerization of OmoMYC, arguing that OmoMYC homodimers are more stable than 
OmoMYC/MYC and OmoMYC/MAX heterodimers (Figure 2d). We concluded that OmoMYC 
forms stable homodimers and heterodimers with MYC and MAX in cells and that both 
OmoMYC homodimers and OmoMYC/MYC heterodimers bind specifically to DNA. 
 
OmoMYC blunts promoter invasion by oncogenic MYC levels 
To determine how OmoMYC binds to chromatin, we stably expressed HA-tagged OmoMYC 
in U2OS cells that express a doxycycline-inducible allele of MYC, which we have previously 
characterized24 (Figure 3a). We performed chromatin-immunoprecipitation coupled with high-
throughput sequencing (ChIP-sequencing) using an α-HA and an α-MYC antibody, which 
recognizes the amino-terminal 262 amino acids of MYC that are not present in OmoMYC. 
ChIP results of individual genes and inspection of multiple individual regions of the genome 
showed that overall binding patterns of MYC and OmoMYC were very similar (Figure 3b, 
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Supplementary Figure S4a,b). This result was confirmed by a global analysis of all MYC 
binding sites, which showed a highly significant overlap in binding sites (Figure 3c). 
Consistent with these findings, de novo motif analysis confirmed that OmoMYC binding sites 
were enriched in both consensus (CACGTG) and non-consensus E-box (CANNTG) binding 
sites (Supplementary Figure S4c). In addition, OmoMYC, like MYC, showed a preference for 
promoters and enhancers with an open chromatin structure even in the absence of a cognate 
binding site26, 27 (Supplementary Figure S4d,e).  
U2OS cells express relatively low levels of endogenous MYC that are identical to levels 
found in several non-transformed proliferating cell lines; upon doxycycline-induction, levels 
increase to those found in colon carcinoma and HeLa cells28. These “oncogenic” levels of 
MYC bind to additional sites not occupied by physiological MYC levels (“promoter 
invasion”)24, 29. Quantitative analyses show that promoters differ strongly in the MYC 
concentration at which binding is half-maximal (EC50) and that EC50 values stratify 
functionally different classes of MYC target genes28. To test how OmoMYC affects chromatin 
association of MYC, we performed ChIP-sequencing for MYC at both concentrations in the 
presence and absence of OmoMYC. Expression of OmoMYC reduced binding of MYC at 
both promoters and non-promoter binding sites (Figure 3d). Consistent with its molecular 
properties, the decrease in MYC binding caused by OmoMYC was stronger on consensus E-
box sequences than on non-consensus E-boxes or on binding sites that lacked an E-box 
(Figure 3d, Supplementary Figure S5a).	
Importantly, the decrease in MYC binding was not uniform for all promoters. Rather, 
OmoMYC had little influence on MYC binding at promoters that are highly occupied by 
physiological levels of MYC and to which no additional MYC is recruited when MYC levels 
increase to supra-physiological levels (Figure 3e). In contrast, OmoMYC decreased the 
recruitment of MYC (“invasion”) to promoters upon doxycycline induction (Figure 3e). Indeed, 
the effect of OmoMYC on MYC binding correlated with the EC50 values for the respective 
gene (Supplementary Figure S5b). One way to rationalize these findings is the suggestion 
that OmoMYC competes with MYC/MAX complexes for binding to DNA. MYC/MAX binding 
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at promoters that are highly occupied by physiological MYC levels is stabilized by 
protein/protein interactions of the MYC amino-terminus that is not present in OmoMYC and 
therefore are not competed by OmoMYC (see Discussion and Figure 8)28. 
 
OmoMYC attenuates oncogenic MYC-dependent gene expression	
RQ-PCR analyses showed that expression of OmoMYC interferes significantly with induction 
of individual genes by MYC (Figure 4a). To obtain a global picture of OmoMYC-dependent 
gene regulation, we performed RNA-sequencing in the presence and absence of OmoMYC 
without and 30 h after induction of ectopic MYC expression. The analysis showed that 
OmoMYC significantly attenuated both transcriptional activation and repression by MYC 
(Figure 4b). 	
We have previously shown that the change in expression of a given gene in response to 
doxycycline-mediated induction of MYC correlates with the change in occupancy of its 
promoter24, 28. Consistent with the DNA binding data, attenuation of gene regulation by 
OmoMYC was not uniform but was strongest on genes that respond to an increase from 
physiological to supra-physiological level of MYC (Figure 4c, red). The simplest model to 
account for this observation is that OmoMYC competes with MYC/MAX complexes on DNA 
to lower MYC/MAX affinity to its cognate binding sites and thereby blunts the “invasion” of 
low affinity promoters. In support of this notion, we found that the OmoMYC-dependent 
change in expression correlated with the decrease in MYC binding over all MYC target genes 
(Figure 4d).  
To test if specific DNA-binding is required for OmoMYC’s effects on gene regulation, we 
stably expressed two alleles of OmoMYC: one OmoMYC(HER), in which the DNA-binding 
triad in the basic region H12-E16-R20 is mutated to alanine and a second, which carried 
alanine substitutions only at H12 and E16 (OmoMYC(HE)), since mutation of the two 
homologous residues in MYC (H359A-E363A) is sufficient to abolish specific E-box 
recognition (B. Amati, personal communication). We confirmed that both OmoMYC(HER) 
and OmoMYC(HE) accumulate in the nucleus upon stable expression in cells 
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(Supplementary Figure S6a,b). ChIP experiments confirmed that both OmoMYC(HER) and 
OmoMYC(HE) are compromised in their ability to recognize target promoters on DNA (Figure 
4e). Analysis of individual genes showed that both OmoMYC(HE) and OmoMYC(HER) are 
severely compromised in their ability to inhibit MYC-dependent transcription (Figure 4f). This 
was confirmed by RNA-sequencing, which showed that mutation of the basic region largely, 
but not completely abolished the repressive effect of OmoMYC on MYC-dependent 
transcription (Figure 4c, Supplementary Figure S6c). Collectively, the data argue that the 
predominant mode, by which OmoMYC inhibits MYC-dependent gene regulation, is the 
formation of DNA binding-homodimers that compete with MYC/MAX heterodimers for their 
target DNA.  	
OmoMYC-regulated genes define a signature characteristic of multiple MYC-driven tumors	
GSE analyses showed that OmoMYC reverted expression of multiple well-characterized 
MYC target gene signatures (Figure 5a). This suggested that OmoMYC might blunt an 
expression program that is characteristic of human tumors characterized by high MYC 
expression. GSE analyses showed that this is indeed the case and that OmoMYC target 
genes identify tumors with high MYC levels in human neuroblastoma, multiple myeloma, 
medulloblastoma, colon carcinoma, and Burkitt lymphoma (Figure 5b,c). Notably, the most 
consistent overlap was observed for genes that are repressed by OmoMYC, which largely 
correspond to genes that are activated by MYC. While OmoMYC-activated (MYC-repressed) 
genes discriminated medulloblastomas and multiple myelomas with high MYC levels, they 
did not reliably identify colon carcinoma and human Burkitt lymphoma, possibly indicating 
that direct repression by MYC is not a predominant mode of gene regulation in these entities. 
Consistent with this notion and the human data, OmoMYC-repressed genes, but not 
OmoMYC-activated genes, discriminated both pre-tumoral stages from control lymphocytes 
and also frank lymphomas from pre-tumoral stages in mouse models of MYC-driven 
lymphomagenesis7 (Figure 5d). In contrast, sets of high affinity MYC target genes that are 
not competed or regulated by OmoMYC discriminated normal B-cells from both pre-
Jung et al.                           OmoMYC structure and function 	
- 11 -	
lymphomagenic cells and lymphomas, but were unable to discriminate pre-lymphomagenic 
cells from frank lymphomas (Supplementary Figure S7a). Furthermore, OmoMYC had little 
effect on expression of genes regulated by endogenous MYC during mitogenic stimulation of 
fibroblasts (Figure 5e). OmoMYC-regulated genes also discriminated pancreatic carcinomas 
with high MYC expression and particularly bad prognosis from less aggressive carcinomas 
(Supplementary Figure S7b). We concluded that OmoMYC regulates a group of MYC target 
genes that is characteristic of tumor entities expressing high levels of MYC across multiple 
entities. 	
 
Identification of OmoMYC target genes critical for growth of MYC-dependent tumor cells	
GSE analysis of the OmoMYC-regulated genes revealed a spectrum of functions that have 
been identified in previous analyses of MYC target genes1 (Supplementary Figure S8a). We 
therefore performed a targeted shRNA screen to identify candidate genes that can explain 
the ability of OmoMYC to specifically interfere with tumor cell growth. Cultures of U2OS cells 
expressing OmoMYC revealed rapid selection against the ectopically expressed OmoMYC, 
which precluded the analysis of effects of OmoMYC on cell growth (L.A.J., unpublished 
observation). We therefore used an inducible allele to analyze OmoMYC function in cells 
derived from KRAS-driven pancreatic tumors, since previous work had established that MYC 
levels and function are critical for growth of these tumors in vivo24. We generated cell lines 
that express OmoMYC in a doxycycline-inducible manner in KRAS/p53mut cells (KPC) (Figure 
6a). OmoMYC suppressed both adherent and anchorage-independent growth of KPCs 
(Figure 6b, Supplementary Figure S8b,c). RNA-sequencing showed that genes regulated by 
OmoMYC in KPCs are highly similar to those regulated in U2OS cells (Supplementary Figure 
S8d).	
We next generated a focused shRNA library that targets genes that are activated by MYC 
and repressed by OmoMYC (Figure 6c, Supplementary Table S5). Each of the genes was 
covered by five shRNAs, and the representation of individual shRNAs was determined by 
high-throughput sequencing after 4 days of induction. This focused screen identified three 
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significant hits, BOP1, RPN13 (also known as ADRM1) and ATAD3A (Figure 6d, 
Supplementary Table S6). Both MYC and OmoMYC bound to the promoters of BOP1 and 
ATAD3A confirming they are direct targets of both (Supplementary Figure S9a,b). Like the 
entire set of OmoMYC-regulated genes, expression of all three genes correlated with MYC 
expression in several human tumor entities (Supplementary Figure S9c). Independent work 
had established that expression of each of these genes is enhanced in multiple human 
tumors and can be prognostic for tumor outcome30-33. Indeed, inhibitors of ribosome 
biogenesis (e.g. of RNA Polymerase I) and inhibitors of ADRM1 are currently being explored 
for tumor therapy32, 34. We confirmed that both inhibitors of RNA Polymerase I (CX-5461) and 
of ADRM1 (RA 190) suppress growth of KPCs, validating the results of the screen (Figure 
6e). Titration of both inhibitors revealed no evidence for synergy, consistent with the fact that 
they inhibit independent cell biological processes (Supplementary Figure S9d). 	
The most significant hit in this screen is ATAD3A, a protein that promotes fusion of 
mitochondria35. ATAD3A is a downstream target of the mTOR pathway and required for cell 
growth in Drosophila and Caenorhabditis elegans35, 36. Consistent with these observations 
and the screening results, shRNA-mediated depletion of ATAD3A attenuated growth of KPCs 
(Figure 6f,g). We confirmed that ATAD3A localizes to mitochondria (Figure 7a). Changes in 
mitochondrial dynamics alter mitochondrial metabolism in response to cell growth and 
metabolism. We speculated that uncoupling of both processes might lead to the 
accumulation of reactive oxygen species (ROS). In support of this notion, shRNA-mediated 
suppression of ATAD3A using two shRNAs caused an increase in mitochondrial ROS that 
correlated with the decrease in ATAD3A expression (Figure 7b,d). Depletion of PLD6, a 
MYC-induced gene that encodes a phospholipase that initiates mitochondrial fusion also 
sharply increased ROS levels in mitochondria, supporting the notion that this increase is due 
to altered mitochondrial dynamics37 (Figure 7c). Maintaining a redox balance is of particular 
importance for transformed cells due to a prevalence of anabolic processes that consume 
reducing equivalents. Indeed, depletion of ATDA3A caused MYC-dependent apoptosis in 
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U2OS cells (Figure 7e). We concluded that ATAD3A-dependent changes in mitochondrial 
dynamics are critical for the survival of cells that express high levels of MYC.  
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Discussion 	
Here, we have solved the structure and studied the properties of OmoMYC to understand 
how OmoMYC can discriminate between physiological and oncogenic functions of MYC. 
Consistent with the intended design, we find that OmoMYC forms homodimers that are 
stabilized by interactions of residues that are mutated in OmoMYC20. The overall structure of 
OmoMYC (including the DNA binding domain) is highly similar to the structures of other 
HLH/Zip proteins. OmoMYC homodimers interact with DNA in the same manner as MAX 
homodimers and MYC/MAX heterodimers21, 38. This suggests a model, in which OmoMYC 
competes with MYC/MAX complexes for binding to DNA, and is in line with previous 
observations that ectopically expressed OmoMYC can be chromatin-immunoprecipitated at 
MYC target sites25. In support of this model, we found that mutant alleles of OmoMYC with 
reduced affinity to E-box containing DNA are compromised in their ability to antagonize 
MYC-dependent gene expression. We confirm previous findings that OmoMYC forms 
heterodimers with MYC and MAX 25, although both estimation of heterodimer stability from 
the crystal structure and immunoprecipitation experiments from cells suggest that 
OmoMYC/MYC and OmoMYC/MAX heterodimers have lower stabilities than OmoMYC 
homodimers. OmoMYC/MYC heterodimers are capable of binding to DNA. Therefore the 
reduction in chromatin association of MYC caused by OmoMYC homodimers is attenuated 
by formation of OmoMYC/MYC heterodimers. Furthermore, it is possible, that 
OmoMYC/MYC heterodimers regulate transcription similar to MYC/MAX heterodimers. If this 
is the case, the biological effects of OmoMYC are attenuated by OmoMYC/MYC 
heterodimers, implying that the design of more potent OmoMYC alleles is possible that shift 
the dimerization balance towards even more stable homodimer formation.  
 
OmoMYC competes with MYC/MAX heterodimers on chromatin and thereby reduces their 
occupancy at cognate binding sites. OmoMYC blunts the binding of MYC to low affinity sites 
(“promoter invasion”) that is characteristic of the high levels of MYC observed in many 
human tumors, but has a significantly weaker effect on MYC binding to sites bound by 
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physiological MYC levels (Figure 8). We hypothesize that the ability of OmoMYC to 
discriminate different classes of target genes is due to the fact that MYC binding to 
promoters with an apparent high affinity is stabilized by local protein/protein interactions in 
addition to contacts with DNA (Figure 8)28. This suggestion is supported by the recent 
identification of core promoter factors that bind to MYC and stabilize its binding to promoters 
and by biochemical and mathematical modeling analyses arguing that both binding of MYC 
to DNA and to promoter–bound factors is required to account for the chromatin binding 
behavior of MYC in cells 27, 28, 39, 40. Many expression profiles have been identified that are 
characteristic for tumor entities or subgroups that express particularly high MYC or N-MYC 
levels. OmoMYC reverts a MYC-dependent gene expression program that is recognizable in 
multiple human and mouse tumor entities, providing a model how it can have broad anti-
tumor activity. At the same time, OmoMYC has significantly less effect on gene expression 
programs of normal proliferating cells, correlating with its low toxicity in vivo. 
 
Genes that responded particularly strongly to OmoMYC did not encode proteins that are 
functionally linked to one specific cellular process. We therefore performed an shRNA screen 
to identify downstream targets via which OmoMYC may suppress tumor cell growth. The 
screen identified BOP1, which is part of a trimeric complex (“PeBoW”) that is essential for 
processing and maturation of mammalian 5.8S and 28S ribosomal RNAs41, ADRM1 (also 
known as RPN13), an ubiquitin acceptor on the proteasome42 and ATAD3A, a calcium-
regulated protein involved in mitochondrial dynamics and transport from the ER to the 
mitochondrion35, 43. Ribosome biogenesis and protein translation are essential for normal cell 
growth. Nevertheless, both processes are enhanced to supra-physiological levels in MYC-
driven tumors and targeting these processes opens specific therapeutic windows16, 44. 
Likewise, targeting ADRM1 using small molecule inhibitors opens a wide therapeutic window 
between normal and tumor cells32. Similarly, we find that cells expressing high levels of MYC 
have an enhanced dependence on ATAD3A for survival, suggesting that targeting ATAD3A 
may also be effective against MYC-dependent tumor cells. ATAD3A has anti-apoptotic 
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functions in tumors, potentially via its effects on mitochondrial dynamics33, 45.  Collectively, 
our findings suggest that individual genes encoding rate-limiting proteins involved in basic 
cell biological processes respond to the difference between physiological and supra-
physiological MYC levels and that OmoMYC specifically inhibits tumor cell growth since it 
suppresses expression of this group of genes. A similar picture has emerged from studies of 
nucleotide biosynthesis genes: despite pervasive binding of MYC to promoters of nucleotide 
biosynthetic enzymes46, deregulation of a single rate-limiting enzyme, phosphoribosyl-
pyrophosphate synthetase 2 (PRPS2), promotes the increased nucleotide biosynthesis of 
MYC-transformed cells47. A complete understanding of how to mimic OmoMYC´s efficacy 
with small molecule inhibitors will therefore require an analysis of its target genes in an in 
vivo setting.  
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Materials and methods  
A detailed description of all materials and methods can be found in the Supplementary 
Information.  
Expression and purification of recombinant OmoMYC, MYC and MAX protein 
OmoMYC, MYC (aa353-434) and MAX were expressed as N-terminally His-tagged or GST-
tagged proteins in E.coli and chromatographically purified using the ÄKTA protein purification 
systems (GE Healthcare, Chicago, IL, USA). 
 
Crystallization of OmoMYC 
OmoMYC apo crystals were grown using the vapor diffusion method in sitting drops and 
analyzed at beamline ID23-1 at the ESRF (Grenoble, France) to a resolution of 1.95 Å. The 
DNA-bound OmoMYC complex was generated by crystallizing his-tagged OmoMYC in the 
presence of an E-box oligonucleotide38. The data set was collected at beamline 14.1 (BESSY 
II, Berlin, Germany) to a resolution of 2.7 Å. The structures were solved via Phaser by 
molecular replacement using the MYC/MAX dimer (1NKP)21 as initial search model. PDB 
codes for OmoMYC are: 5I4Z (apo structure) and 5I50 (DNA-bound structure).  
 
Gel mobility shift assays 
Increasing concentrations of recombinant OmoMYC, MAX and MYC were used for binding 
reactions with a double stranded, 5’CY3 labeled DNA substrate (CM1)48. Where indicated, 
antibodies were added prior to DNA addition. Kd values were calculated using Prism 
(GraphPad Software, La Jolla, CA, USA) assuming complete dimer formation with a four 
parameter non-linear regression. 
 
Cell culture 
U2OS tet-on-MYC cells24 and KPCs (Ptf1a+/Cre;Kras+/LSL-G12D;p53loxP/R172H) were 
cultured according to standard conditions; U2OS were authenticated via STR Analysis; KPCs 
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were a kind gift of Jens Siveke (Technical University of Munich, Germany). All cell lines were 
routinely tested for mycoplasma contamination.  
 
Pooled negative-selection shRNA screening 
A custom shRNA library directed against OmoMYC target genes (Supplementary Table S5) 
was cloned into the inducible lentiviral vector RT3GEPIR49. KPC cells were transduced with 
the pooled library and cultivated in the presence or absence of doxycycline for four days. 
shRNA sequences were PCR recovered from genomic DNA of harvested cells and changes 
in shRNA frequencies were determined by next-generation sequencing with an Illumina 
GAIIx (Illumina, San Diego, CA, USA).  
 
Bioinformatic analysis and statistics 
Information on data processing for ChIP- and RNA-sequencing is at GEO: GSE77328. For 
binned data the mean of each bin is plotted. Sorting of the binned data was done using 
independent experiments. Regression lines were estimated using linear models and 
corresponding p-values were calculated using 2-tailed t-distribution. Statistical significant 
differences between two regression lines were determined using an analysis of covariances 
(ANCOVA). p-values for box plots were calculated with non-parametric 2-tailed Wilcoxon-
Mann-Whitney tests. 	
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Figure Legends 	
Figure 1: Structure and DNA-binding properties of OmoMYC.	
(a) Schematic representation of the apo OmoMYC crystal structure. Mutations that 
distinguish OmoMYC from MYC are highlighted in red. Boxes on the right highlight the 
carboxy-terminal disulfide bridge (top), the hydrogen bond network involving N77 
(middle) and hydrogen bonds bridged by two water molecules between T63 (bottom). 
Images were generated using PyMOL. (b: basic region; HLH: helix-loop-helix region; Zip: 
leucine zipper). 
(b) Crystal structure of the OmoMYC homodimer bound to a consensus E-box. The 
CACGTG motif is highlighted in blue. The boxes on the right illustrate base-specific 
interactions of one arm of the OmoMYC homodimer (green) to one half of the palindromic 
E-box sequences of the double-stranded DNA (grey). For comparison, base-specific 
protein-DNA contacts of MYC in the MYC/MAX structure (1NKP)21 are illustrated in the 
upper box. 
(c) Interactions that distinguish the OmoMYC homodimer (upper panel) from the MYC/MAX 
heterodimer (lower panel) as deduced from the crystal structures. Mutations of OmoMYC 
relative to MYC are shown as red dots. Dotted lines indicate interactions of the carboxy-
terminus (boxed), which is not present in the MYC/MAX crystal structure and can 
therefore not be compared reliably. IA: interaction. 
 
Figure 2: OmoMYC preferentially forms homodimers and binds to DNA in vitro. 
(a) Electrophoretic mobility shift assays (EMSAs) comparing binding of MAX, MYC/MAX, 
OmoMYC and MYC/OmoMYC dimers to a consensus E-box oligonucleotide. Protein 
concentrations (calculated as dimers) are indicated. The upper band shows protein-
bound Cy3-labeled DNA (bound DNA) while the lower band reflects unbound labeled 
DNA (free DNA). Protein concentrations are shown for dimers. (n≥3; n indicates the 
number of independent biological replicates.) 
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(b) Determination of dissociation constants (Kd) of the protein-DNA complexes from EMSAs 
as shown in panel (a). Fractions of bound DNA (% bound) were plotted against the 
logarithmic protein concentration (cprot) (n≥3). Error bars indicate SEM. Kd values 
obtained by a four parameter non-linear fit using GraphPad Prism are shown in the table 
to the right. CI: confidence interval. 
(c) U2OS cells stably expressing HA-tagged OmoMYC or a mutant allele, in which the 
penultimate cysteine (C91) was replaced by a serine were treated with 100 µM H2O2 
where indicated. SDS-PAGE was performed under reducing or non-reducing conditions 
(± DTT) and blots probed with an α-HA antibody. CDK2 was used as a loading control 
(n=4). *: non-specific bands, upper arrow: covalently linked dimer, lower arrow: monomer, 
vec: empty vector control, Omo: HA-OmoMYC, CS: HA-OmoMYC(CS) mutant. 
(d) Immunoprecipitation of FLAG-tagged OmoMYC with α-FLAG antibody in U2OS cells 
expressing exogenous HA-tagged OmoMYC or MYC (HA-tagged or doxycycline-induced 
untagged). Co-immunoprecipitated proteins were compared to 8 % (α-FLAG and α-MYC 
immunoblots) or 4 % (α-HA and α-MAX immunoblots) input material (n=3). *: heavy 
chain, DOX: doxycycline, vec: empty vector control. 
 
Figure 3: OmoMYC attenuates chromatin binding of MYC.	
(a) Immunoblot showing doxycycline-mediated MYC expression in U2OS cells and in U2OS 
cells expressing OmoMYC. Where indicated, cells were treated with doxycycline 
(1 µg/ml; 8 h). Lysates were probed with α-MYC, α-HA and α-CDK2 antibodies as 
indicated (n=3).  
(b) Examples for ChIP-sequencing tracks at the NPM1 and ARC loci. ChIP-sequencing was 
performed with the indicated antibodies from control cells or cells expressing HA-
OmoMYC (both U2OS) before or after addition of doxycycline (1 µg/ml; 8 h). Input and 
HA-ChIP-OmoMYC traces are shown as controls. 
(c) Heat maps comparing binding of MYC and OmoMYC proteins to chromatin. MYC peaks 
were split into peaks close to RNA polymerase II transcribed genes and intergenic 
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regions. Shown is a window of ±5 kb surrounding the MYC binding sites. Loci are ranked 
according to MYC occupancy.  
(d) Tag density plots comparing MYC binding to core promoters (top, n=1 868) and to non-
promoter binding sites (bottom, n=2 543) in the presence and absence of OmoMYC. 
Traces are shown for MYC binding before (endogenous MYC) and after addition of 
doxycycline. Only binding sites with consensus E-box sequences are shown.  
(e) Diagram demonstrating reduced “invasion” by oncogenic MYC levels in the presence of 
OmoMYC. All directly bound promoters (n=7 379) were binned into 25 bins according to 
recruitment of MYC in an independent experiment24. The x-axis shows recruitment in the 
absence, y-axis in the presence of OmoMYC. The p-value was calculated using a linear 
model and a t-test with an offset of 1. MYC recruitment was calculated by counting the 
number of tags in a region of +/-100 bp around the summit of the MYC peak, input was 
subtracted and a fold change between +DOX and -DOX was calculated. 
 
Figure 4: OmoMYC attenuates oncogenic MYC-dependent gene expression.	
(a) RQ-PCR assays documenting expression of CAMKV after doxycycline-mediated 
induction of MYC (1 µg/ml; 8 h) in control U2OS cells and in cells constitutively 
expressing HA-OmoMYC. Error bars indicate SD of technical triplicates (n=3). 
(b) Box plots documenting globally attenuated activation and repression by MYC in the 
presence of OmoMYC in U2OS cells. Left plot shows absolute values for all significantly 
MYC regulated genes (FDR<0.05), plots on the right show the effect of OmoMYC on 
MYC activation and repression. The box plots encompass data points between the first 
and third quartiles. A horizontal line indicates the median, whiskers extend to 1.5x 
interquartile range and outliers are not shown. The p-values were calculated using two-
sided, paired Wilcoxon signed rank tests. 
(c) Correlation of MYC-dependent gene regulation in U2OS control cells (x-axis) and in 
U2OS cells expressing either OmoMYC or OmoMYC (HE) (y-axis). Shown are the log2 
fold-change (FC) values of gene regulation in cells after doxycycline-mediated induction 
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of MYC (1 µg/ml; 30 h). All expressed genes were sorted for MYC-regulation according to 
an independent dataset and binned into 38 bins with 490 genes each. A linear model was 
used to calculate regression lines for binned data of OmoMYC and OmoMYC(HE) 
expressing cells. r: Pearson correlation coefficient. 
(d) Correlation of OmoMYC-dependent change in gene expression with change in promoter 
occupancy by MYC. All MYC-bound promoters were binned into 17 bins with 400 genes 
each and sorted for expression changes upon MYC-induction. The p-value indicated 
significance of linear correlation and was calculated with a two-tailed Student’s t-test. 
(e) qPCR analysis of a ChIP experiment performed in U2OS cells expressing HA-OmoMYC, 
one of the two alleles of OmoMYC (HER-AAA or HE-AA) or empty vector (vec). Primer 
pairs are located in the promoter regions of NPM1, NCL, FBXW8, CAMKV and in an 
intergenic region (Ctr). Error bars are showing SD of technical triplicates (n=2). 
(f) RQ-PCR assays documenting expression of CAMKV after doxycycline-mediated 
induction of MYC (1 µg/ml; 30 h) in control cells and in cells constitutively expressing 
OmoMYC, OmoMYC(HER) or OmoMYC(HE). Error bars indicate SD of technical 
triplicates (n=6).  
 
Figure 5: OmoMYC reverts MYC-dependent gene expression programs of human and 
murine tumors.	
(a) The panels show gene set enrichment analyses (GSEA) of genes regulated in response 
to doxycycline-mediated MYC induction and of OmoMYC-regulated genes in U2OS cells. 
Shown are normalized enrichment scores (NES) and q-values of well-characterized 
MYC-activated and -repressed gene sets. GSE analyses were performed with 
signal2noise metric, 1000 permutations and the C2 gene set collection of MSigDB50. 
(b) GSE analysis of three gene sets containing OmoMYC-repressed (n=383), OmoMYC-
activated (n=137) and MYC-activated & OmoMYC-repressed (n=148) genes comparing 
gene expression of stage 4 versus stage 1-3 neuroblastomas (GSE16476). 
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(c) GSEA of gene expression changes of different human tumors characterized by high MYC 
or MYCN expression. Expression data from human tumors are sets GSE16476, 
GSE37382, GSE4475, GSE26760, and GSE39582. 
(d) GSEA of different stages of a mouse model of B-cell lymphomagenesis. Expression data 
from murine Eµ-MYC tumors are from data set GSE51008. 
(e) GSEA of gene expression changes in murine embryonic fibroblasts (MEF) in which MYC-
activation7 or MYC-knockout51 is induced by 4-OHT treatment. Gene sets are defined as 
in b. 	
Figure 6: Identification of critical OmoMYC target genes.	
(a) Immunoblot of doxycycline-mediated OmoMYC expression in KPCs. Where indicated, 
cells were treated with doxycycline (1 µg/ml) for 48 h. Lysates were probed with α-HA 
and α-CDK2 antibodies (n=3). 
(b) Analysis of cell growth in KPCs expressing either control vector (vec) or doxycycline-
inducible OmoMYC. Where indicated, were grown in the presence of doxycycline 
(1 µg/ml). Cells were seeded at equal densities and either counted after 3 days (upper 
part) or stained with crystal violet after 5 days of growth (lower part). Data are presented 
as mean ±SD of biological triplicates. p-values were calculated using a paired two-tailed 
Student's t-test. 
(c) Flow chart showing the selection process of target genes for a focused shRNA screen. 
From all expressed genes (RPKM>1), those genes were selected that are significantly 
activated by doxycycline-induced MYC expression and simultaneously repressed by 
OmoMYC expression in doxycycline treated cells. These genes were further filtered for 
druggability (Supplementary Table S5). 
(d) Results of the targeted shRNA-screen in KPC cells. Waterfall plots documenting z-scores 
for log2FC in shRNA frequencies between doxycycline treated (induced shRNA 
expression) and untreated cell populations after 4 days of growth. Dotted lines indicate 
z=±3. The left panel shows shRNAs targeting MYC and luciferase as positive and 
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negative controls, respectively. The right panel highlights shRNAs targeting ATAD3A, 
BOP1 and ADRM1.  
(e) Dose response curves after RNA Pol I (CX-5461) and ADRM1 (RA 190) inhibition. KPCs 
were treated with the indicated compounds for 48 hours and percent cell viability was 
measured using an MTT assay. Data are presented as mean ± SD of 6 technical 
replicates. IC50 values are shown as mean ± SD (n=3). 
(f) Immunoblot of doxycycline-mediated knockdown of Atad3a in KPCs. Where indicated, 
cells were treated with doxycycline (1 µg/ml) for 48 h. Lysates were probed with α-Atad3a 
and α-Cdk2 antibodies. 
(g) Analysis of cell growth in KPCs expressing either shRNA targeting luciferase or Atad3a. 
Where indicated, were grown in the presence of doxycycline (1 µg/ml). Cells were 
seeded at equal densities and either counted after 3 days (upper part) or stained with 
crystal violet after 4 days of growth (lower part). Data are represented as mean ± SD 
(n=3). The p-values were calculated using a paired two-tailed Student's t-test. 	
Figure 7: Functional analysis of ATAD3A.	
(a) Mitochondrial localization of ATAD3A in U2OS cells. Mitochondria were immunostained 
with AF532 (upper part) and ATAD3A with AF647 (middle part). The overlay 
demonstrates co-localization of mitochondria (green) and ATAD3A (magenta) (lower 
part). 
(b) Mitochondrial ROS levels in U2OS control cells and in cells expressing shRNAs targeting 
ATAD3A after doxycycline-induced MYC expression (1 µg/ml; 30 h). Data are 
represented as mean ± SD (n=3). p-values were calculated using a two-tailed, paired t-
test. 
(c) Mitochondrial ROS levels in cells transfected with control siRNA or siRNA targeting PLD6 
after doxycycline-induced MYC expression. Data are represented as mean ± SD (n=3). 
(d) Immunoblot showing ATAD3A knockdown by two independent shRNA constructs in 
U2OS cells. Lysates were probed with α-ATAD3A and α-CDK2 antibodies. 
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(e) MYC-dependent induction of apoptosis in U2OS control cells and cells with shRNA 
mediated knockdown of ATAD3A. Where indicated, MYC expression was induced by 
doxycycline (1 µg/ml; 36 or 48 h). AnnexinV was used to stain apoptotic cells. Data are 
represented as mean ± SD (n=3). The p-values were calculated using a two-tailed, paired 
t-test. 	
Figure 8: Chromatin binding and gene regulation by OmoMYC.	
We propose that OmoMYC homodimers compete with MYC/MAX heterodimers for binding to 
DNA. Binding of MYC/MAX to promoters that are highly occupied by physiological MYC 
levels is stabilized by protein/protein interactions involving the MYC amino-terminus that are 
not outcompeted by OmoMYC. As a result, competition by OmoMYC is not uniform and is 
more effective on “low-affinity” promoters that are invaded by oncogenic MYC levels. 
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